Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARG_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARG_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARG_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001056329 | Thyroid | HT | negative regulation of phosphorus metabolic process | 54/1272 | 442/18723 | 1.99e-05 | 4.60e-04 | 54 |
GO:000974329 | Thyroid | HT | response to carbohydrate | 36/1272 | 253/18723 | 2.00e-05 | 4.63e-04 | 36 |
GO:00970664 | Thyroid | HT | response to thyroid hormone | 9/1272 | 26/18723 | 3.25e-05 | 6.90e-04 | 9 |
GO:003166729 | Thyroid | HT | response to nutrient levels | 56/1272 | 474/18723 | 3.66e-05 | 7.57e-04 | 56 |
GO:007099730 | Thyroid | HT | neuron death | 45/1272 | 361/18723 | 5.89e-05 | 1.12e-03 | 45 |
GO:001407420 | Thyroid | HT | response to purine-containing compound | 24/1272 | 148/18723 | 5.93e-05 | 1.13e-03 | 24 |
GO:007155918 | Thyroid | HT | response to transforming growth factor beta | 35/1272 | 256/18723 | 6.03e-05 | 1.13e-03 | 35 |
GO:000974625 | Thyroid | HT | response to hexose | 31/1272 | 219/18723 | 8.12e-05 | 1.41e-03 | 31 |
GO:007156018 | Thyroid | HT | cellular response to transforming growth factor beta stimulus | 34/1272 | 250/18723 | 8.48e-05 | 1.46e-03 | 34 |
GO:00512718 | Thyroid | HT | negative regulation of cellular component movement | 45/1272 | 367/18723 | 8.73e-05 | 1.48e-03 | 45 |
GO:20001468 | Thyroid | HT | negative regulation of cell motility | 44/1272 | 359/18723 | 1.05e-04 | 1.75e-03 | 44 |
GO:190121427 | Thyroid | HT | regulation of neuron death | 40/1272 | 319/18723 | 1.31e-04 | 2.08e-03 | 40 |
GO:005140226 | Thyroid | HT | neuron apoptotic process | 33/1272 | 246/18723 | 1.40e-04 | 2.17e-03 | 33 |
GO:007145324 | Thyroid | HT | cellular response to oxygen levels | 26/1272 | 177/18723 | 1.62e-04 | 2.43e-03 | 26 |
GO:004259423 | Thyroid | HT | response to starvation | 28/1272 | 197/18723 | 1.64e-04 | 2.45e-03 | 28 |
GO:00400138 | Thyroid | HT | negative regulation of locomotion | 46/1272 | 391/18723 | 1.94e-04 | 2.84e-03 | 46 |
GO:007133319 | Thyroid | HT | cellular response to glucose stimulus | 23/1272 | 151/18723 | 2.20e-04 | 3.15e-03 | 23 |
GO:000974920 | Thyroid | HT | response to glucose | 29/1272 | 212/18723 | 2.47e-04 | 3.45e-03 | 29 |
GO:004352320 | Thyroid | HT | regulation of neuron apoptotic process | 29/1272 | 212/18723 | 2.47e-04 | 3.45e-03 | 29 |
GO:000167819 | Thyroid | HT | cellular glucose homeostasis | 25/1272 | 172/18723 | 2.53e-04 | 3.52e-03 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARG | SNV | Missense_Mutation | novel | c.2006N>T | p.Ser669Leu | p.S669L | Q86W56 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARG | insertion | Frame_Shift_Ins | novel | c.1451_1452insCT | p.Arg485PhefsTer3 | p.R485Ffs*3 | Q86W56 | protein_coding | | | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
PARG | SNV | Missense_Mutation | rs4614387 | c.1453N>T | p.Arg485Trp | p.R485W | Q86W56 | protein_coding | deleterious(0) | benign(0.072) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PARG | SNV | Missense_Mutation | novel | c.517N>G | p.Gln173Glu | p.Q173E | Q86W56 | protein_coding | tolerated_low_confidence(0.16) | benign(0.001) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PARG | SNV | Missense_Mutation | novel | c.2515N>C | p.Glu839Gln | p.E839Q | Q86W56 | protein_coding | tolerated(0.06) | benign(0.312) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PARG | SNV | Missense_Mutation | novel | c.815G>A | p.Gly272Asp | p.G272D | Q86W56 | protein_coding | tolerated_low_confidence(0.64) | benign(0.049) | TCGA-VS-A8EB-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | PD |
PARG | SNV | Missense_Mutation | novel | c.1199C>G | p.Ser400Cys | p.S400C | Q86W56 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.628) | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PARG | deletion | Frame_Shift_Del | novel | c.2808delN | p.Tyr936Ter | p.Y936* | Q86W56 | protein_coding | | | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
PARG | SNV | Missense_Mutation | novel | c.2173N>G | p.Thr725Ala | p.T725A | Q86W56 | protein_coding | deleterious(0.02) | benign(0.359) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARG | SNV | Missense_Mutation | novel | c.1865C>G | p.Ser622Cys | p.S622C | Q86W56 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-AA-3662-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PR |